Early response to alpha interferon in a patient affected by hairy cell leukemia
F Di Raimondo1, D Murolo, G Milone
11a Cattedra di Ematologia, Università di Catania, Italy.
Insights
Interferon (IFN) therapy induced remission in a hairy cell leukemia (HCL) patient despite initial adverse events. The patient achieved sustained remission after two separate IFN treatment courses, highlighting its potential efficacy.
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- Hairy cell leukemia (HCL) is a rare B-cell malignancy.
- Treatment options for relapsed HCL can be limited.
- Interferon (IFN) has been explored as a therapeutic agent for HCL.
Observation:
- A splenectomized patient with relapsed HCL received interferon (IFN) therapy.
- Initial IFN treatment was halted due to adverse events including fever, jaundice, and respiratory distress.
- Following recovery, the patient achieved a complete remission of HCL.
Findings:
- The patient remained in remission for two years without therapy.
- Upon relapse, re-treatment with IFN resulted in a partial remission.
- This partial remission has been maintained for 28 months without further treatment.
Implications:
- This case suggests that interferon (IFN) can be effective in inducing and maintaining remission in hairy cell leukemia (HCL), even after initial adverse events.
- The observation warrants further investigation into the mechanisms of IFN action in HCL.
- Interferon (IFN) may represent a viable treatment option for select patients with relapsed hairy cell leukemia (HCL).
Abstract:
A 61-year-old splenectomized male patient affected by hairy cell leukemia (HCL) in relapse was treated with interferon (IFN) at a dosage of 3 x 10(6) U/day. After only 11 days of treatment, IFN was stopped because the patient developed fever, jaundice and respiratory distress. Upon recovery from this infectious episode, the patient was judged to be in complete remission of HCL on the basis of clinical and laboratory findings, and he remained off-therapy for 2 years. When an overt relapse occurred, the patient was again treated with IFN and, after a very short time, he achieved a new, good partial remission that is maintained 28 months later without treatment. This observation remains speculative for understanding the mechanism of action of IFN in other comparable HCL cases.
More Related Videos
10:01Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes
Published on: February 11, 2015
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018